Amarin's (NASDAQ:AMRN) share price has yo-yoed after the company gained Food and Drug Administration approval for its triglyceride-lowering drug, Vascepa, this summer. However, investors are still interested in this exciting biotech story, and there are reasons to be both bullish and bearish on this stock.

In the following video, Austin Smith talks with health care analyst and author of our premium research report on Amarin, Max Macaluso, about one specific reason to buy shares of this company and one reason to sell.